Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245895 · ClinicalTrials.gov registry record · Phase 2
Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00245895 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 20 participants.
The verdict
NCT00245895, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective. Sometimes prostate cancer patients have low red blood cell counts (low hemoglobin) from various treatments they are receiving, such as chemotherapy. The red blood cells deliver oxygen to the tissue. This then helps give the patient more energy.
Interventions
- DRUG Aranesp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245895
The ClinicalTrials.gov registry entry for NCT00245895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aranesp is the first listed.
NCT00245895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245895 about?
NCT00245895 is a clinical study titled "Study of Aranesp to Treat Anemia in Prostate Cancer Patients.". The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective. Sometimes prostate cancer patients have low red blood cell counts (low hemoglobin) from various treatments they are receiving, such as che...
What is the current status of trial NCT00245895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-04. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00245895?
The interventions under investigation include: Aranesp (DRUG).
Who is sponsoring clinical trial NCT00245895?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.